The Cancer Biology and Progression Laboratory

patriciamadureira

Location

Building 8, Laboratory 2.22

Department of Biomedical Sciences and Medicine.

University of Algarve

Phone: +351 289 244 443

pamadureira@ualg.pt

Team Members

Patrícia Madureira (Principal Investigator)
Joana Rosa (PhD, postdoc candidate)
Henrique Cardoso (PhD student, co-supervision)
Gisela Serrão Fernandes (PhD candidate)
Ana Rita Monteiro (MSc student)

About the CBPL

The Cancer Biology and Progression Laboratory (CBPL) focus on understanding how cancer cells manipulate cellular systems. Cancer cells typically have higher levels of reactive oxygen species (ROS) compared to normal cells; leading to elevated ROS-dependent signalling that activate survival, proliferation and metastatis. However, excessive ROS can induce DNA, lipid and protein damage leading to cell death. Consequently cancer cells up-regulate ROS scavenging proteins to avoid this associated toxicity. A key research theme within the CBPL is to investigate the role played by antioxidant proteins in the regulation of oncogenic ROS-dependent signaling. The second key research theme is to investigate the regulation of plasmin activity that is highly associated with cancer cell invasion and metastasis.

Team

patriciamadureira_resize
patriciamadureura_team

Publications (2008-2017)

Miller VA, Madureira PA, Kamaludin AA, Komar J, Sharma V, Sahni G, Thelwell C, Longstaff C, Waisman DM. “Mechanism of plasmin generation by S100A10”. Thromb Haemost. 2017 Apr 6. doi: 10.1160/TH16-12-0936.

Hill R, Madureira PA, Ferreira B, Baptista I, Machado S, Colaço L, Dos Santos M, Liu N, Dopazo A, Ugurel S, Adrienn A, Kiss-Toth E, Isbilen M, Gure AO, Link W. “TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT”. Nat Commun. 2017 Mar 9; 8:14687. doi: 10.1038/ncomms14687.

Madureira PA, Bharadwaj AG, Bydoun M, Garant K, O’Connell P, Lee P, Waisman DM. “Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10.” Oncotarget. 2016 Jun 24. doi: 10.18632/oncotarget.10279.

Castaldo SA, Freitas JR, Conchinha NV and Madureira PA, “The tumorigenic roles of the cellular REDOX regulatory systems.” Oxid Med Cell Longev. 2016; 2016:8413032. doi: 10.1155/2016/8413032.

Hill R, Rabb M, Madureira PA, Clements D, Gujar SA, Waisman DM, Giacomantonio CA and Lee PWK. “Gemcitabine requires PUMA to drive tumour regression: implications for colon and pancreatic cancer therapy.”  Cell Death Dis. 2013 Sep 5;4:e791. 

Madureira PA and Waisman DM. Annexin A2: The importance of being redox sensitive. Int. J. Mol. Sci. 201314(2), 3568-3594. Review.

Link W, Madureira PA and Hill R. Identifying new targets for personalized cancer therapy. eLS. 2013. Review.

Madureira PA, O’Connell PA, Surette AP, Miller VA, Waisman DM. The Biochemistry and Regulation of S100A10: A Multifunctional Plasminogen Receptor Involved in Oncogenesis. J Biomed Biotechnol. 2012: 353687.

Madureira PA, Hill R, Lee PWK, Waisman DM, “Genotoxic agents promote the nuclear accumulation of annexin A2: role of annexin A2 in mitigating DNA damage” PLoS ONE. Nov 30; 7(11): e50591. doi: 10.1371/journal.pone.0050591.

Madureira PA, Hill R, Miller VA, Giacomantonio C, Lee PWK, Waisman DM “Annexin A2 is a novel cellular redox regulatory protein involved in tumorigenesis.”Oncotarget. 2011 Dec; 2 (12):1075-93.

Hill R, Madureira PA, Waisman DM and Lee PWK. ” DNA-PKCS binding to p53 on the p21WAF1/CIP1 promoter blocks transcription resulting in cell death.”Oncotarget. 2011 Dec; 2 (12):1094-108.  Selected by Prof. Mikhail V. Blagosklonny (Editor in Chief) for “Featured Article, News and views”. Highlighted by Professor R. Smith and featured in “Global Medical Discovery” June 7th, 2012.

 Madureira PA, Surette AP, Phipps KD, Taboski MAS, Miller VA and Waisman DM. “The role of the annexin A2 heterotetramer (AIIt) in vascular fibrinolysis.”Blood. 2011 Nov 3;118(18):4789-97. Review.

 Surette AP, Madureira PA, Phipps KD, Miller VA, Svenningsson P, Waisman DM. “Regulation of fibrinolysis by S100A10 in vivo.” Blood. 2011 Sep 15; 118(11):3172-81.

 O’Connell PA, Madureira PA, Berman JN, Liwski RS, Waisman DM. “Regulation of S100A10 by the PML-RAR-α oncoprotein” Blood. 2011 Apr 14; 117(15):4095-105.

 Madureira PA, Waisman DM . S100A10 (S100 calcium binding protein A10). Atlas Genet Cytogenet Oncol Haematol. October 2008.

 Hill R, Leidal AM, Madureira PA, Gillis LD, Waisman DM, Chiu A, Lee PW. “Chromium-mediated apoptosis: Involvement of DNA-dependent protein kinase (DNA-PK) and differential induction of p53 target genes” DNA Repair (Amst). 2008 Sep 1;7(9):1484-99.

 Hill R, Leidal AM, Madureira PA, Gillis LD, Cochrane HK, Waisman DM, Chiu A, Lee PW. “Hypersensitivity to chromium-induced DNA damage correlates with constitutive deregulation of upstream p53 kinases in p21-/- HCT116 colon cancer cells” DNA Repair (Amst). 2008 Feb 1;7(2):239-52.

Representative Images

Project Grants

2015-2020: Exploratory project from Foundation for Science and Technology (FCT), Ref: IF/00614/2014/CP1234 – “Identification and characterization of redox regulatory proteins involved in cancer progression”.

Investigator FCT grant; ref: IF/00614/2014. “Identification and characterization of redox regulatory proteins involved in cancer progression”

Collaboration Protocols

Secondment agreement with Brain Tumour Research Centre of Excellence, Portsmouth, U.K.

Leave a Reply

Your email address will not be published. Required fields are marked *